{"disease":{"id":"immunization","name":"immunization"},"drugs":{"marketed":[{"drug_id":"licensed-influenza-vaccine-3","indication_name":"Intranasal influenza vaccine for active immunization against influenza disease caused by influenza virus types A and B, in individuals 6 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Assorted Licensed Hand Sanitizer Grape 01","generic_name":"Licensed Influenza Vaccine 3","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Influenza virus hemagglutinin protein","drug_class":"Vaccine","quality_score":37,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"pneumococcal-20-valent-conjugate-vaccine","indication_name":"Pneumococcal Immunization","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pneumococcal 20-valent conjugate vaccine","generic_name":"pneumococcal-20-valent-conjugate-vaccine","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"For intramuscular use only. One dose (0.5 mL) of Pneumococcal 20-valent conjugate vaccine should be ","quality_score":null,"revenue":null,"mechanism":"For intramuscular use only. One dose (0.5 mL) of Pneumococcal 20-valent conjugate vaccine should be "}],"offLabel":[],"totalMarketed":1,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT02456077","title":"Strengthening Physician Communication About HPV Vaccines","phase":"NA","overall_status":"COMPLETED","enrollment_count":93582,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT02133391","title":"Accountable Care Organizations/ Public Health Collaborative","phase":"NA","overall_status":"COMPLETED","enrollment_count":78354,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT02993965","title":"State Immunization Information Systems to Improve HPV Vaccination Rates","phase":"NA","overall_status":"COMPLETED","enrollment_count":77716,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT02609035","title":"Immunization Services Model for Adult Rate Improvement","phase":"NA","overall_status":"COMPLETED","enrollment_count":22301,"lead_sponsor_name":"Pharmacy Quality Alliance","has_results":false},{"nct_id":"NCT06833957","title":"Preparing for Maternal GBS Vaccine Trials in Africa","phase":"","overall_status":"RECRUITING","enrollment_count":18100,"lead_sponsor_name":"Barcelona Institute for Global Health","has_results":false},{"nct_id":"NCT04038333","title":"Financing Strategies of Influenza Vaccination in China","phase":"","overall_status":"COMPLETED","enrollment_count":13542,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT04444518","title":"Increasing Influenza and Tdap Vaccination of Pregnant Women","phase":"NA","overall_status":"COMPLETED","enrollment_count":12760,"lead_sponsor_name":"University of Rochester","has_results":true},{"nct_id":"NCT03355989","title":"Evaluation of Conditional Cash Transfers (CCTs) for Immunization","phase":"NA","overall_status":"COMPLETED","enrollment_count":11197,"lead_sponsor_name":"Interactive Research and Development","has_results":false},{"nct_id":"NCT05505760","title":"Testing Content Delivery Models for MomConnect","phase":"NA","overall_status":"UNKNOWN","enrollment_count":8867,"lead_sponsor_name":"IDinsight","has_results":false},{"nct_id":"NCT03445117","title":"Increasing the Uptake of Influenza and Pneumococcal Vaccines Among High-Risk Adult Patients Through GP Clinics","phase":"NA","overall_status":"COMPLETED","enrollment_count":8837,"lead_sponsor_name":"Tan Tock Seng Hospital","has_results":false},{"nct_id":"NCT06144580","title":"The Impact of Community Health Workers on the Uptake of Preventative Care Services in London, UK","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":8400,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT05437510","title":"Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":8057,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT05570630","title":"VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination","phase":"NA","overall_status":"COMPLETED","enrollment_count":6911,"lead_sponsor_name":"University of Rochester","has_results":true},{"nct_id":"NCT06800885","title":"Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT07445763","title":"TARSILA Real-World Evidence Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Inova Medical","has_results":false},{"nct_id":"NCT06185647","title":"Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis","phase":"","overall_status":"COMPLETED","enrollment_count":4924,"lead_sponsor_name":"Hôpital Armand Trousseau","has_results":false},{"nct_id":"NCT06387511","title":"Increasing Measles Vaccination Coverage Through Supplementation With an SQ-LNS Incentive in Children Aged 6-23 Months","phase":"NA","overall_status":"COMPLETED","enrollment_count":3814,"lead_sponsor_name":"Alliance for International Medical Action","has_results":false},{"nct_id":"NCT04799808","title":"Saxon SARS-CoV-2 Infection and Vaccination Study in Dialysis Patients, Solid Organ Recipients and Staff","phase":"","overall_status":"UNKNOWN","enrollment_count":3500,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT07164430","title":"The Impact of the 2025 Infant and Maternal Respiratory Syncytial Virus (RSV) Prevention Program on RSV-related Hospitalisations in the Australian Capital Territory","phase":"","overall_status":"COMPLETED","enrollment_count":2792,"lead_sponsor_name":"Nicola Irwin","has_results":false},{"nct_id":"NCT07103148","title":"A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2440,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05794113","title":"Comparing the Use of a Mobile App for Surveillance of Adverse Events Following Influenza Immunization to a Web-Based Platform","phase":"NA","overall_status":"COMPLETED","enrollment_count":2408,"lead_sponsor_name":"The Ottawa Hospital","has_results":false},{"nct_id":"NCT06824207","title":"Repeated Cross Sectional Surveillance Study To Determine the Respiratory Syncytial Virus (RSV) Immunization Rates in German Infants","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2400,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT06824194","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2360,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06397768","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":2226,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT07348692","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2195,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT04498832","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2100,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT06059456","title":"Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24","phase":"","overall_status":"COMPLETED","enrollment_count":2078,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT03705455","title":"Immunization Schedule Alert Platform","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1800,"lead_sponsor_name":"Lifespan Healthcare Resource Limited","has_results":false},{"nct_id":"NCT06736041","title":"Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1714,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT06891417","title":"Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":1560,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06413121","title":"Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1557,"lead_sponsor_name":"Serum Institute of India Pvt. Ltd.","has_results":false},{"nct_id":"NCT04024228","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1539,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT06686654","title":"Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1530,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT03310762","title":"Immunization Reminder Bracelets Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":1445,"lead_sponsor_name":"Interactive Research and Development","has_results":false},{"nct_id":"NCT04302675","title":"Adapting Motivational Interviewing for Maternal Immunizations (MI4MI)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1350,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT04143061","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1328,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT05513053","title":"Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1308,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT05104385","title":"Hacettepe University COVID-19 Vaccinated's Health Cohort- Students of Health Sciences","phase":"","overall_status":"COMPLETED","enrollment_count":1223,"lead_sponsor_name":"Hacettepe University","has_results":false},{"nct_id":"NCT04936776","title":"Pediatric Vaccinations","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1203,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT05317884","title":"Email-based Reminders Promoting Recommended Pediatric Preventative Visits","phase":"NA","overall_status":"COMPLETED","enrollment_count":1186,"lead_sponsor_name":"Geisinger Clinic","has_results":false},{"nct_id":"NCT05661890","title":"Seasonal Influenza and Pneumococcal Vaccination in the Elderly","phase":"","overall_status":"COMPLETED","enrollment_count":1166,"lead_sponsor_name":"Lokman Hekim University","has_results":false},{"nct_id":"NCT06975878","title":"Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1092,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05069649","title":"Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1057,"lead_sponsor_name":"Materia Medica Holding","has_results":true},{"nct_id":"NCT06765187","title":"A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire","phase":"","overall_status":"COMPLETED","enrollment_count":1007,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06695117","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":980,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06695130","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":980,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06361875","title":"A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":910,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT03107312","title":"Bioarray for the Serological Assessment of Immunity Against Vaccine-preventable Infections","phase":"","overall_status":"UNKNOWN","enrollment_count":900,"lead_sponsor_name":"Jena University Hospital","has_results":false},{"nct_id":"NCT05639894","title":"Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":865,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT05721274","title":"Community Engagement and Conditional Incentives to Accelerate Polio","phase":"NA","overall_status":"COMPLETED","enrollment_count":840,"lead_sponsor_name":"Aga Khan University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}